Cargando…

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Detalles Bibliográficos
Autores principales:	Greenberger, Lee M., Saltzman, Larry A., Senefeld, Jonathon W., Johnson, Patrick W., DeGennaro, Louis J., Nichols, Gwen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421105/ https://www.ncbi.nlm.nih.gov/pubmed/34509182 http://dx.doi.org/10.1016/j.ccell.2021.09.001

Ejemplares similares

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 “Booster” Vaccination - Observational Data from the LLS National Registry
por: Greenberger, Lee M, et al.
Publicado: (2021)

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)

Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies during the Omicron (B.1.1.529) Surge: Data from the Patient-Reported Leukemia & Lymphoma Society National Registry
por: Reddy, Sneha T, et al.
Publicado: (2022)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

2334. The effectiveness of bivalent COVID-19 booster among patients with hematologic malignancies
por: Aleissa, Muneerah M, et al.
Publicado: (2023)

Danger ahead: COVID-19 infections after vaccination
por: Greenberger, Lee M., et al.
Publicado: (2022)

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
por: Vargas, Leonardo, et al.
Publicado: (2022)

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain
por: Takano, Tomohiro, et al.
Publicado: (2023)

Antibody response to SARS-CoV-2 booster vaccines
por: Loving, Hanna S., et al.
Publicado: (2022)

Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies
por: Huang, Chien-Tzu, et al.
Publicado: (2023)

Bispecific Antibodies in the Treatment of Hematologic Malignancies
por: Duell, Johannes, et al.
Publicado: (2019)

Antiphospholipid Antibodies and Lipids in Hematological Malignancies
por: Barreno-Rocha, Sonia Guadalupe, et al.
Publicado: (2022)

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
por: Uaprasert, Noppacharn, et al.
Publicado: (2022)

1590P Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies
por: Zakurdaeva, K., et al.
Publicado: (2021)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

HLA Antibody Rates Are Not Increased in a Regional Group of Male COVID-19 Convalescent Plasma Donors
por: Juskewitch, Justin E., et al.
Publicado: (2021)

No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study)
por: Kling, Kendall D., et al.
Publicado: (2023)

Sars-CoV2 Antibody Responses in Patients with Hematological Malignancies Following Anti-CD20 Therapy
por: Guerra, Veronica A, et al.
Publicado: (2021)

Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
por: Piñana, José Luis, et al.
Publicado: (2022)

COVID-19 immune response in hematologic malignancies: analysis of COVID-19 anti-spike antibodies in previously infected and uninfected patients
por: Lanka, SM, et al.
Publicado: (2023)

Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2
por: Brady, Molly, et al.
Publicado: (2021)

SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation
por: Hoff, Fieke W., et al.
Publicado: (2023)

Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
por: Krekeler, Carolin, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
por: Chang, Andres, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
por: Quiroga, Borja, et al.
Publicado: (2022)

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies
por: Han, Yizhao, et al.
Publicado: (2020)

Bispecific Antibodies in Hematological Malignancies: A Scoping Review
por: Omer, Mohamed H., et al.
Publicado: (2023)

Antibody detection of SARS-CoV spike and nucleocapsid protein
por: Chang, Mau-Sun, et al.
Publicado: (2004)

Antibody-mediated immunity to SARS-CoV-2 spike
por: Errico, John M., et al.
Publicado: (2022)

SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
por: Woo, Patrick C.Y., et al.
Publicado: (2005)

Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
por: Stellini, Roberto, et al.
Publicado: (2022)

The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration
por: Swadźba, Jakub, et al.
Publicado: (2023)

SARS-COV-2 antibodies after booster vaccination. Identification of subgroups with poor response
por: Ayuso García, B., et al.
Publicado: (2023)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_41hhh62acu3oqoa4q3g93visqs